康宁公司（纽约证券交易所：GLW）和Medichem S.A.已成功展示使用康宁的商业规模连续生产活性药物成分（API）^®Advanced-Flow™G4碳化硅反应器。

Medichem能够在几个生产活动中在CGMP条件下生产有机金属化合物API，现在可以在工业规模的连续流量多用途单元中重复其结果。康宁提供了一种交钥匙设备解决方案，包括符合ATEX指令和G4反应器的自动馈电系统。

"Our innovative technology has made robust, industrial, continuous-flow production a successful part of Medichem’s manufacturing operation," said Dr. Yi Jiang, global business director for康宁反应堆技术。"Our reactors’ patented heart-shaped design and engineering expertise provided Medichem with a customized reactor solution to help them achieve a smaller footprint and a short return on investment. We look forward to continuing our excellent collaboration with Medichem."

在传统设备呈现挑战后，Medichem转换为流量反应器技术。Medichem的适当的流量装置随着康宁的连续流量反应堆实现了这种令人鼓舞的结果，即Medichem决定通过整合一个来评估缩放康宁^®Advanced-Flow™G1反应堆。一致的质量和可靠的性能属性LED它们以实现相同的过程康宁^®Advanced-Flow™G4反应堆在植物规模。这导致产量和工业纯度的无缝扩大，从而实现了本申请的主要挑战。

Medichem致力于有机金属过程，每次缩减时都会急剧下降产量。在用连续流动进行一些测试之后，它们能够以相同的产量和比其常规批处理过程更好地再现和缩放。

康宁反应堆使得专业，精细和制药行业的高质量化学品的优化成本。与批量反应器相比，康宁^®先进的-Flow™ reactors can enable 100 times enhancement in mixing, 1,000 times improvement in heat transfer performance, and seamless and efficient scale-up from the lab to full-scale production. Corning's proprietary reactor technology is compact, adaptable, and seamlessly scalable. Corning is working with key customers around the world to develop various flow reactors that optimize chemical processing results. Economic concerns, environmental impact, and regulatory authorities are helping to make continuous-flow reactors more mainstream.

前瞻性和警示陈述
此新闻稿包含“前瞻性陈述”（在1995年私营证券诉讼改革法案的含义内），这是基于当前对康宁的财务业绩和业务运营的预期和假设，这涉及可能导致的大量风险和不确定性实际结果有所不同。这些风险和不确定性包括：全球政治，经济和业务条件的影响;金融和信贷市场的条件;货币波动;税率;产品需求和行业能力;竞赛;依赖集中的客户群;制造业效率; cost reductions; availability of critical components and materials; new product commercialization; pricing fluctuations and changes in the mix of sales between premium and non-premium products; new plant start-up or restructuring costs; possible disruption in commercial activities due to terrorist activity, armed conflict, political or financial instability, natural disasters, adverse weather conditions, or major health concerns; adequacy of insurance; equity company activities; acquisition and divestiture activities; the level of excess or obsolete inventory; the rate of technology change; the ability to enforce patents; product and components performance issues; retention of key personnel; stock price fluctuations; and adverse litigation or regulatory developments. These and other risk factors are detailed in Corning's filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the day that they are made, and Corning undertakes no obligation to update them in light of new information or future events.

关于Corning Incorporated.
康宁（www.akinfefatou.com.的）is one of the world's leading innovators in materials science. For more than 160 years, Corning has applied its unparalleled expertise in specialty glass, ceramics, and optical physics to develop products that have created new industries and transformed people's lives. Corning succeeds through sustained investment in R&D, a unique combination of material and process innovation, and close collaboration with customers to solve tough technology challenges. Corning's businesses and markets are constantly evolving. Today, Corning's products enable diverse industries such as consumer electronics, telecommunications, transportation, and life sciences. They include damage-resistant cover glass for smartphones and tablets; precision glass for advanced displays; optical fiber, wireless technologies, and connectivity solutions for high-speed communications networks; trusted products that accelerate drug discovery and manufacturing; and emissions-control products for cars, trucks, and off-road vehicles.

一种bout Medichem
Medichem（www.medichem.es.的）is an independently-owned API manufacturer, headquartered in Barcelona (Spain) with more than 40 years of experience in this market. Medichem has two FDA inspected plants (Spain and Malta) and 3 R&D centers located in Spain, Malta and China. The company has more than 250 people working at various locations (Spain, Malta and China) and delivers products to more than 60 countries (United States, the European Union and Japan among others). Medichem is recognized for its broad pipeline of new products indicated for the treatment of diseases in many therapeutic areas, such as Central Nervous System, Cardiovascular, Gastrointestinal, Ophthalmic, etc... Medichem has a sister company, Combino Pharm, which manufactures, develops and markets generic pharmaceutical products. Both companies offer Contract Manufacturing services (regular and Highly Potent APIs and FDF).